Recombinant IgE antibody engineering to target EGFR

Cancer Immunology, Immunotherapy

Volumn 61, Issue 9, 2012, Pages 1565-1573

  Spillner, Edzard ^a   Plum, Melanie ^a   Blank, Simon ^a   Miehe, Michaela ^b   Singer, Josef ^c,d   Braren, Ingke ^b  

^a UNIVERSITY OF HAMBURG   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

AllergoOncology symposium in writing; Antibody engineering; EGFR; Recombinant IgE; Tumor targeting

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; CANERTINIB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY 225; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY 425; EPITOPE; ERLOTINIB; GEFITINIB; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN E RECEPTOR; IRINOTECAN; MATUZUMAB; NIMOTUZUMAB; PANITUMUMAB; RITUXIMAB; TRASTUZUMAB; TYRPHOSTIN; UNCLASSIFIED DRUG; ZALUTUMUMAB;

ANTIBODY ENGINEERING; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; COLORECTAL CARCINOMA; CONFERENCE PAPER; CYTOTOXICITY; DEGRANULATION; DRUG TARGETING; ENZYME ACTIVATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOGLOBULIN E; PROTEIN ENGINEERING; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84866541757     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1287-4     Document Type: Conference Paper

References (67)

1. Downward J, Yarden Y, Mayes E, Scrace G, Totty N, Stockwell P, Ullrich A, Schlessinger J, Waterfield MD (1984) Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 307:521-527 (Pubitemid 14135812)
2. Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW, Lee J, Yarden Y, Libermann TA, Schlessinger J et al (1984) Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309:418-425 (Pubitemid 14102443)
3. Citri A, Yarden Y (2006) EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7:505-516 (Pubitemid 44036456)
4. Gadella TW Jr, Jovin TM (1995) Oligomerization of epidermal growth factor receptors on A431 cells studied by time-resolved fluorescence imaging microscopy. A stereochemical model for tyrosine kinase receptor activation. J Cell Biol 129:1543-1558
5. Lemmon MA, Bu Z, Ladbury JE, Zhou M, Pinchasi D, Lax I, Engelman DM, Schlessinger J (1997) Two EGF molecules contribute additively to stabilization of the EGFR dimer. EMBO J 16:281-294 (Pubitemid 27049386)
6. Lenferink AE, Pinkas-Kramarski R, van de Poll ML, van Vugt MJ, Klapper LN, Tzahar E, Waterman H, Sela M, van Zoelen EJ, Yarden Y (1998) Differential endocytic routing of homo-and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J 17:3385-3397 (Pubitemid 28279512)
7. Baulida J, Kraus MH, Alimandi M, Di Fiore PP, Carpenter G (1996) All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J Biol Chem 271:5251-5257 (Pubitemid 26075021)
8. Levkowitz G, Waterman H, Ettenberg SA, Katz M, Tsygankov AY, Alroy I, Lavi S, Iwai K, Reiss Y, Ciechanover A, Lipkowitz S, Yarden Y (1999) Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/ Sli-1. Mol Cell 4:1029-1040 (Pubitemid 30054908)
9. Hommelgaard AM, Lerdrup M, van Deurs B (2004) Association with membrane protrusions makes ErbB2 an internalizationresistant receptor. Mol Biol Cell 15:1557-1567 (Pubitemid 38401807)
10. Avraham R, Yarden Y (2011) Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat Rev Mol Cell Biol 12:104-117
11. Sato K, Sato A, Aoto M, Fukami Y (1995) Site-specific association of c-Src with epidermal growth factor receptor in A431 cells. Biochem Biophys Res Commun 210:844-851
12. Biscardi JS, Maa MC, Tice DA, Cox ME, Leu TH, Parsons SJ (1999) c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J Biol Chem 274:8335-8343
13. Olayioye MA, Beuvink I, Horsch K, Daly JM, Hynes NE (1999) ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases. J Biol Chem 274:17209-17218
14. Wilde A, Beattie EC, Lem L, Riethof DA, Liu SH, Mobley WC, Soriano P, Brodsky FM (1999) EGF receptor signaling stimulates SRC kinase phosphorylation of clathrin, influencing clathrin redistribution and EGF uptake. Cell 96:677-687 (Pubitemid 29122810)
15. Hynes NE (2000) Tyrosine kinase signalling in breast cancer. Breast Cancer Res 2:154-157 (Pubitemid 32223579)
16. Ford AC, Grandis JR (2003) Targeting epidermal growth factor receptor in head and neck cancer. Head Neck 25:67-73 (Pubitemid 36005333)
17. Wheeler DL, Dunn EF, Harari PM (2010) Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 7:493-507
18. Buerger C, Nagel-Wolfrum K, Kunz C, Wittig I, Butz K, Hoppe-Seyler F, Groner B (2003) Sequence-specific peptide aptamers, interacting with the intracellular domain of the epidermal growth factor receptor, interfere with Stat3 activation and inhibit the growth of tumor cells. J Biol Chem 278:37610-37621 (Pubitemid 37175284)
19. Li N, Nguyen HH, Byrom M, Ellington AD (2011) Inhibition of cell proliferation by an Anti-EGFR aptamer. PLoS ONE 6:e20299
20. Yamazaki H, Kijima H, Ohnishi Y, Abe Y, Oshika Y, Tsuchida T, Tokunaga T, Tsugu A, Ueyama Y, Tamaoki N, Nakamura M (1998) Inhibition of tumor growth by ribozyme-mediated suppression of aberrant epidermal growth factor receptor gene expression. J Natl Cancer Inst 90:581-587 (Pubitemid 28204801)
21. Riemer AB, Kurz H, Klinger M, Scheiner O, Zielinski CC, Jensen-Jarolim E (2005) Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies. J Natl Cancer Inst 97:1663-1670 (Pubitemid 41672232)
22. Yang L, Jiang H, Shi B, Wang H, Li J, Yao M, Li Z (2010) Identification and characterization of Ch806 mimotopes. Cancer Immunol Immunother 59:1481-1487
23. Hartmann C, Muller N, Blaukat A, Koch J, Benhar I, Wels WS (2010) Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response. Oncogene 29:4517-4527
24. Mendelsohn J (1997) Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 3:2703-2707 (Pubitemid 28133130)
25. Masui H, Kawamoto T, Sato JD, Wolf B, Sato G, Mendelsohn J (1984) Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 44:1002-1007 (Pubitemid 14152782)
26. Beum PV, Mack DA, Pawluczkowycz AW, Lindorfer MA, Taylor RP (2008) Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes. J Immunol 181:8120-8132
27. Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, Murphy BA, Satinover SM, Hosen J, Mauro D, Slebos RJ, Zhou Q, Gold D, Hatley T, Hicklin DJ, Platts-Mills TA (2008) Cetuximab-induced anaphylaxis and IgE specific for galactosealpha-1,3-galactose. N Engl J Med 358:1109-1117 (Pubitemid 351398485)
28. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG (2001) Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 38:17-23 (Pubitemid 32194591)
29. de Bono JS, Rowinsky EK (2002) Therapeutics targeting signal transduction for patients with colorectal carcinoma. Br Med Bull 64:227-254 (Pubitemid 35238589)
30. Harding J, Burtness B (2005) Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today (Barc) 41:107-127 (Pubitemid 40461533)
31. Bleeker WK, Lammerts van Bueren JJ, van Ojik HH, Gerritsen AF, Pluyter M, Houtkamp M, Halk E, Goldstein J, Schuurman J, van Dijk MA, van de Winkel JG, Parren PW (2004) Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J Immunol 173:4699-4707 (Pubitemid 39280705)
32. Murthy U, Basu A, Rodeck U, Herlyn M, Ross AH, Das M (1987) Binding of an antagonistic monoclonal antibody to an intact and fragmented EGF-receptor polypeptide. Arch Biochem Biophys 252:549-560 (Pubitemid 17026484)
33. Rodeck U, Williams N, Murthy U, Herlyn M (1990) Monoclonal antibody 425 inhibits growth stimulation of carcinoma cells by exogenous EGF and tumor-derived EGF/TGF-alpha. J Cell Biochem 44:69-79 (Pubitemid 20350937)
34. Seiden MV, Burris HA, Matulonis U, Hall JB, Armstrong DK, Speyer J, Weber JD, Muggia F (2007) A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. Gynecol Oncol 104:727-731
35. Schiller JH (2008) Developments in epidermal growth factor receptor-targeting therapy for solid tumors: focus on matuzumab (EMD 72000). Cancer Invest 26:81-95
36. Mateo C, Moreno E, Amour K, Lombardero J, Harris W, Perez R (1997) Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. Immunotechnology 3:71-81 (Pubitemid 27197395)
37. Suarez Pestana E, Greiser U, Sanchez B, Fernandez LE, Lage A, Perez R, Bohmer FD (1997) Growth inhibition of human lung adenocarcinoma cells by antibodies against epidermal growth factor receptor and by ganglioside GM3: involvement of receptor-directed protein tyrosine phosphatase(s). Br J Cancer 75:213-220 (Pubitemid 27019565)
38. Luwor RB, Johns TG, Murone C, Huang HJ, Cavenee WK, Ritter G, Old LJ, Burgess AW, Scott AM (2001) Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. Cancer Res 61:5355-5361 (Pubitemid 32694909)
39. Schmiedel J, Blaukat A, Li S, Knochel T, Ferguson KM (2008) Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. Cancer Cell 13:365-373 (Pubitemid 351446197)
40. Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6:443-446 (Pubitemid 30208162)
41. Pander J, Heusinkveld M, Van der Straaten T, Jordanova ES, Baak-Pablo R, Gelderblom H, Morreau H, van der Burg SH, Guchelaar HJ, van Hall T (2011) Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab. Clin Cancer Res 17:5668-5673
42. Neuberger MS (1983) Expression and regulation of immunoglobulin heavy chain gene transfected into lymphoid cells. EMBO J 2:1373-1378
43. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT (1984) Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci U S A 81:6851-6855 (Pubitemid 15221019)
44. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G (1986) Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321:522-525 (Pubitemid 16052256)
45. Gritzmacher CA, Liu FT (1987) Expression of a recombinant murine IgE in transfected myeloma cells. J Immunol 138:324-329 (Pubitemid 17218438)
46. Furtado PB, McElveen JE, Gough L, Armour KL, Clark MR, Sewell HF, Shakib F (2002) The production and characterisation of a chimaeric human IgE antibody, recognising the major mite allergen Der p 1, and its chimaeric human IgG1 anti-idiotype. Mol Pathol 55:315-324 (Pubitemid 35193260)
47. Rodin DV, Kolesnikov VA, Srdiuk OV, Zelenina IA, Zelenin AV, Deev SM (2000) Synthesis of chimeric IgE in vivo after ballistic transfection of immunoglobulin genes in various mouse tissues. Mol Biol (Mosk) 34:18-23
48. Boel E, Verlaan S, Poppelier MJ, Westerdaal NA, Van Strijp JA, Logtenberg T (2000) Functional human monoclonal antibodies of all isotypes constructed from phage display library-derived single-chain Fv antibody fragments. J Immunol Methods 239:153-166 (Pubitemid 30256027)
49. Braren I, Blank S, Seismann H, Deckers S, Ollert M, Grunwald T, Spillner E (2007) Generation of human monoclonal allergenspecific IgE and IgG antibodies from synthetic antibody libraries. Clin Chem 53:837-844 (Pubitemid 46744238)
50. Christensen LH, Riise E, Bang L, Zhang C, Lund K (2010) Isoallergen variations contribute to the overall complexity of effector cell degranulation: effect mediated through differentiated IgE affinity. J Immunol 184:4966-4972
51. Lundberg K, Lindstedt M, Larsson K, Dexlin L, Wingren C, Ohlin M, Greiff L, Borrebaeck CA (2008) Augmented Phl p 5-specific Th2 response after exposure of dendritic cells to allergen in complex with specific IgE compared to IgG1 and IgG4. Clin Immunol 128:358-365
52. Madritsch C, Flicker S, Scheiblhofer S, Zafred D, Pavkov-Keller T, Thalhamer J, Keller W, Valenta R (2011) Recombinant monoclonal human immunoglobulin E to investigate the allergenic activity of major grass pollen allergen Phl p 5. Clin Exp Allergy 41:270-280
53. Braren I, Greunke K, Umland O, Deckers S, Bredehorst R, Spillner E (2007) Comparative expression of different antibody formats in mammalian cells and Pichia pastoris. Biotechnol Appl Biochem 47:205-214 (Pubitemid 47218255)
54. McDonnell JM, Calvert R, Beavil RL, Beavil AJ, Henry AJ, Sutton BJ, Gould HJ, Cowburn D (2001) The structure of the IgE Cepsilon2 domain and its role in stabilizing the complex with its high-affinity receptor FcepsilonRIalpha. Nat Struct Biol 8:437-441 (Pubitemid 32381292)
55. Gunther N, Betzel C, Weber W (1990) The secreted form of the epidermal growth factor receptor. Characterization and crystallization of the receptor-ligand complex. J Biol Chem 265:22082-22085 (Pubitemid 120014268)
56. Dechant M, Weisner W, Berger S, Peipp M, Beyer T, Schneider-Merck T, Lammerts van Bueren JJ, Bleeker WK, Parren PW, van de Winkel JG, Valerius T (2008) Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. Cancer Res 68:4998-5003
57. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM (2005) Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7:301-311 (Pubitemid 40544648)
58. Freeman DSJ, Bass R, Jung K, Ogbagabriel S, Elliott G, Radinsky R (2008) Panitumumab and cetuximab epitope mapping and in vitro activity [abstract]. J Clin Oncol 26:14536
59. Talavera A, Friemann R, Gomez-Puerta S, Martinez-Fleites C, Garrido G, Rabasa A, Lopez-Requena A, Pupo A, Johansen RF, Sanchez O, Krengel U, Moreno E (2009) Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res 69:5851-5859
60. Braren I, Greunke K, Pilette C, Mempel M, Grunwald T, Bredehorst R, Ring J, Spillner E, Ollert M (2011) Quantitation of serum IgE by using chimeras of human IgE receptor and avian immunoglobulin domains. Anal Biochem 412:134-140
61. Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341-354 (Pubitemid 40637826)
62. Karagiannis P, Singer J, Hunt J, Gan SK, Rudman SM, Mechtcheriakova D, Knittelfelder R, Daniels TR, Hobson PS, Beavil AJ, Spicer J, Nestle FO, Penichet ML, Gould HJ, Jensen-Jarolim E, Karagiannis SN (2009) Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells. Cancer Immunol Immunother 58:915-930
63. Bracher M, Gould HJ, Sutton BJ, Dombrowicz D, Karagiannis SN (2007) Three-colour flow cytometric method to measure antibody-dependent tumour cell killing by cytotoxicity and phagocytosis. J Immunol Methods 323:160-171 (Pubitemid 46900832)
64. Jensen-Jarolim E, Mechtcheriakova D, Pali-Schoell I (2010) The targets of IgE: allergen-associated and tumor-associated molecular patterns. In: Penichet ML, Jensen-Jarolim E (eds) Cancer and IgE: introducing the concept of AllergoOncology. Humana Press, New York, pp 231-254
65. Rudman SM, Josephs DH, Cambrook H, Karagiannis P, Gilbert AE, Dodev T, Hunt J, Koers A, Montes A, Taams L, Canevari S, Figini M, Blower PJ, Beavil AJ, Nicodemus CF, Corrigan C, Kaye SB, Nestle FO, Gould HJ, Spicer JF, Karagiannis SN (2011) Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcvarepsilonRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity. Clin Exp Allergy 41:1400-1413
66. Gould HJ, Mackay GA, Karagiannis SN, O'Toole CM, Marsh PJ, Daniel BE, Coney LR, Zurawski VR Jr, Joseph M, Capron M, Gilbert M, Murphy GF, Korngold R (1999) Comparison of IgE and IgG antibody-dependent cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian carcinoma. Eur J Immunol 29:3527-3537 (Pubitemid 29527800)
67. Riemer AB, Untersmayr E, Knittelfelder R, Duschl A, Pehamberger H, Zielinski CC, Scheiner O, Jensen-Jarolim E (2007) Active induction of tumor-specific IgE antibodies by oral mimotope vaccination. Cancer Res 67:3406-3411 (Pubitemid 46724881)